Ovarian Cancer
If it’s your first time on this website, please read the disclaimer section.
Jun 01 – Jun 08, 2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This population-based study analyzed 2.6 million patients across seven countries to evaluate how the COVID-19 pandemic disrupted the incidence and staging of seven major cancer types in 2020. Researchers found that 16% (55,713) of expected cancer cases were missing between April and December 2020, with the highest deficits occurring in prostate (24%), breast (18%), and melanoma (18%) diagnoses. The data reveals significant regional variations, such as a 54% deficit in UK prostate cancer cases, highlighting critical gaps in screening and diagnostic access during lockdowns. These findings underscore a pressing clinical need to address diagnostic backlogs and monitor for potential stage shifts in patients whose diagnoses were delayed by pandemic-related healthcare barriers.
10.1016/S1470-2045(26)00089-6
May 04 – May 11, 2026
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This international multicenter study analyzed 254 patients with stage IC-IV malignant ovarian germ cell tumors (MOGCTs) to identify prognostic risk factors influencing survival. Multivariable analysis revealed that age ≥35 years (HR 2.8), stage III/IV disease (HR 1.4), and nondysgerminoma histology (HR 7.3) significantly worsened cancer-specific survival (CSS). The study demonstrated a 10-year CSS of 83.2% and highlighted that high-dose chemotherapy improves survival outcomes specifically during the first relapse rather than subsequent ones. These findings provide clinicians with critical evidence for risk-stratifying patients and optimizing treatment intensity for advanced-stage MOGCTs, particularly regarding the timing of aggressive salvage therapies.
10.1200/JCO-25-00840
Apr 13 – Apr 20, 2026
Rethinking ovarian cancer III: the past decade and future directions.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This Expert Recommendation, derived from the 15th Helene Harris Memorial Trust International Forum, reviewed a decade of advances, current challenges, and future research priorities in high-grade serous carcinoma (HGSC). HGSC accounts for approximately 80% of ovarian cancer deaths, with 5-year survival rates of 50% overall and only 30% for advanced disease without BRCA1/2 mutations. The forum considered emerging technologies in prevention, early detection, and treatment, directly addressing critical aspects of cancer management. It outlines research priorities to improve outcomes for this highly lethal cancer, offering insights into future clinical directions and potential advancements.
10.1038/s41568-026-00916-0
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This multicentre, phase 3 randomized trial (ENGOT-ov65/KEYNOTE-B96) evaluated the efficacy of adding pembrolizumab to weekly paclitaxel in 643 patients with platinum-resistant recurrent ovarian cancer. The combination significantly improved median progression-free survival (8.3 vs 6.4 months; HR 0.70) and overall survival (17.7 vs 14.0 months; HR 0.82) compared to chemotherapy alone in the overall population. These findings are highly relevant to oncology as they establish a new therapeutic option for a population with historically poor outcomes and limited treatment lines. While the regimen increased grade 3 or worse adverse events (68% vs 55%), the survival benefits support its clinical adoption in recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinomas.
10.1016/S0140-6736(26)00602-1
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3 randomized controlled trial (ROSELLA) evaluated the efficacy of relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel versus nab-paclitaxel monotherapy in 381 patients with platinum-resistant ovarian cancer. The combination therapy demonstrated a statistically significant improvement in overall survival with a hazard ratio of 0.65 (p=0.0004) and a median survival extension of 4.1 months (16.0 vs. 11.9 months). Clinical relevance is high for oncology practice as the 18-month overall survival rate was significantly improved (46% vs. 27%) without the requirement for specific biomarker selection. These findings suggest that relacorilant plus nab-paclitaxel could establish a new standard of care for patients who have progressed after multiple lines of therapy, including bevacizumab and PARP inhibitors.
10.1016/S0140-6736(26)00462-9
Mar 30 – Apr 06, 2026
Interpretation of constitutional cancer predisposition gene variants in 14 765 individuals in the 100 000 Genomes Project cancer arm: a retrospective cohort analysis.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This retrospective cohort study assessed the frequency and nature of constitutional variants in 109 cancer predisposition genes among 14,765 patients with cancer in the UK health-care system. Key findings revealed that 711 (5%) participants harbored a pathogenic or likely pathogenic variant, with CHEK2 (0.82%) and BRCA2 (0.75%) being the most common, and ovarian cancer showing the highest proportion (9%) among specific tumor types. These results are highly relevant for clinicians as they provide a comprehensive understanding of the genetic landscape in cancer patients, informing genetic testing strategies and risk stratification. The study underscores the implications of more expansive genetic testing and the necessity of robust variant interpretation to optimize patient benefit and guide clinical service planning.
10.1016/S1470-2045(25)00766-1
Mar 02 – Mar 09, 2026
Ovarian cancer.
NAT REV DIS PRIMERS · Q1 JOURNAL - RANK #3/332TOP-TIER
This abstract provides an overview of epithelial ovarian cancer (EOC), detailing its diverse characteristics, diagnostic challenges, and current management strategies. It highlights that most high-grade serous EOCs originate from the fallopian tube and that despite recognized genetic susceptibilities, no effective screening is available, leading to common late-stage diagnoses. Management involves surgery and chemotherapy, with poly(ADP-ribose) polymerase inhibitors significantly altering outcomes in some women with defective homologous recombination DNA repair, including those with BRCA1/2 mutations. The abstract is highly relevant to cancer research, detailing the complexities of ovarian cancer, its genetic underpinnings, current treatment paradigms, and the ongoing need for translationally enriched clinical trials to validate biomarkers and targeted therapies.
10.1038/s41572-026-00686-x